Equities analysts expect Express Scripts Holding (NASDAQ:ESRX) to post $25.12 billion in sales for the current quarter, Zacks reports. Twelve analysts have made estimates for Express Scripts’ earnings. The highest sales estimate is $25.54 billion and the lowest is $24.54 billion. Express Scripts reported sales of $24.86 billion during the same quarter last year, which indicates a positive year over year growth rate of 1%. The firm is expected to report its next earnings report after the market closes on Tuesday, February 27th.
On average, analysts expect that Express Scripts will report full-year sales of $25.12 billion for the current financial year, with estimates ranging from $99.22 billion to $100.64 billion. For the next year, analysts anticipate that the company will post sales of $100.92 billion per share, with estimates ranging from $99.93 billion to $103.77 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Express Scripts.
A number of brokerages have recently weighed in on ESRX. BidaskClub downgraded Express Scripts from a “strong-buy” rating to a “buy” rating in a report on Friday, February 2nd. Royal Bank of Canada upgraded Express Scripts from a “sector perform” rating to an “outperform” rating and set a $68.00 price target on the stock in a report on Wednesday, January 31st. Sanford C. Bernstein downgraded Express Scripts from a “market perform” rating to an “underperform” rating and lifted their price target for the company from $55.80 to $77.50 in a report on Tuesday, January 30th. Mizuho set a $86.00 price target on Express Scripts and gave the company a “hold” rating in a report on Wednesday, January 24th. Finally, SunTrust Banks reiterated a “buy” rating and set a $95.00 price target on shares of Express Scripts in a report on Friday, January 12th. Six equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. Express Scripts presently has a consensus rating of “Hold” and an average target price of $78.23.
Express Scripts declared that its Board of Directors has approved a share repurchase plan on Monday, December 18th that permits the company to repurchase 45,000,000 outstanding shares. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.
In other Express Scripts news, VP Glen D. Stettin sold 3,449 shares of the business’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $81.00, for a total value of $279,369.00. Following the transaction, the vice president now owns 33,715 shares in the company, valued at $2,730,915. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Christine Houston sold 10,104 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $70.08, for a total value of $708,088.32. Following the completion of the transaction, the vice president now owns 87,400 shares in the company, valued at approximately $6,124,992. The disclosure for this sale can be found here. Insiders sold 17,001 shares of company stock worth $1,249,505 in the last 90 days. Corporate insiders own 0.68% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of ESRX. Ameriprise Financial Inc. grew its stake in Express Scripts by 23.5% in the third quarter. Ameriprise Financial Inc. now owns 5,233,327 shares of the company’s stock valued at $331,374,000 after purchasing an additional 996,816 shares in the last quarter. Macquarie Group Ltd. boosted its stake in shares of Express Scripts by 8.4% during the 2nd quarter. Macquarie Group Ltd. now owns 11,880,919 shares of the company’s stock worth $758,480,000 after acquiring an additional 922,406 shares in the last quarter. Pzena Investment Management LLC boosted its stake in shares of Express Scripts by 23.6% during the 3rd quarter. Pzena Investment Management LLC now owns 3,509,800 shares of the company’s stock worth $222,241,000 after acquiring an additional 670,922 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Express Scripts by 21.1% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 3,700,527 shares of the company’s stock worth $234,318,000 after acquiring an additional 644,208 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of Express Scripts by 40.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,879,400 shares of the company’s stock worth $119,981,000 after acquiring an additional 541,300 shares in the last quarter. Hedge funds and other institutional investors own 87.86% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/07/25-12-billion-in-sales-expected-for-express-scripts-holding-esrx-this-quarter.html.
Express Scripts Company Profile
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.